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Abstract 
 
Hyperglycemia has been associated with vascular endothelial dysfunction in part by a 
reduction in nitric oxide (NO) production and increased oxidative stress (e.g., increased 
superoxide (SO) and hydrogen peroxide (H2O2). Endothelial-derived NO can be significantly 
reduced by increased SO/H2O2 in part by the activation of NADPH oxidase during 
hyperglycemia. Of the 7 NADPH oxidase isoforms, NADPH oxidase isoform 1 (NOX1) is 
mainly expressed in the vasculature and may play a major role in hyperglycemia induced 
oxidative stress and vascular endothelial dysfunction.  This hypothesis was tested by 
measuring blood NO and H2O2 levels in real time via NO and H2O2 microsensors inserted 
into femoral veins of rats.  Hyperglycemia (e.g., 200 mg/dl) was maintained by an i.v. 
infusion of 30% glucose solution for 3 hours with or without a selective NOX1 inhibitor, 
ML171. Hyperglycemia for 3 hours resulted in significantly higher blood H2O2 levels 
(3.06±0.4 μM, n=9) compared to the saline infused control (P<0.01, n=9).  By contrast, 
ML171 (1 and 5 μM) reduced hyperglycemia-induced H2O2 levels by 1.86±0.61 μM 
(P<0.05, n=8) and 4.85±1.02 μM (P<0.01, n=5) respectively relative to the hyperglycemic 
control after 3 hours.  Hyperglycemia also significantly reduced blood NO levels 
(101.41±10.91 nM, n=8) compared to the saline control (P<0.01, n=8) after 3 hours. By 
contrast, ML171 (1 and 5 μM) significantly attenuated the hyperglycemia induced decrease 
in blood NO levels and increased blood NO levels by 68.48±12.67 nM (P<0.01, n=5) and 
85.95±12.67 nM (P<0.01, n=5) respectively relative to the hyperglycemic control, at the end 
of experiment.  Our results indicate that NOX1 activation may contribute to hyperglycemia-
induced oxidative stress and NO reduction.  Furthermore, inhibition of NOX1 may mitigate 
the deleterious effects of hyperglycemia.  
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 1 
Introduction 
 
Chronic hyperglycemia in diabetic patients is causally related to micro- and 
macro-vascular complications.  Diabetic patients can have decreased wound healing, 
decreased immune function, increased oxidative stress, vascular endothelial 
dysfunction, and increased inflammatory factors1.  Uncontrolled hyperglycemia can 
lead to arterial remodeling and atherogenesis, which may result in blocked arteries 
provoking cardiovascular events. Similarly, acute or stress hyperglycemia in non-
diabetic patients can lead to increased myocardial infarction size, negative post-
surgical consequences, such as infection, increased morbidity, and mortality2.  
However, the vascular damage due to uncontrolled hyperglycemia has not been yet 
contained in medical practice.  Therefore, understanding the underlying cause of 
these vascular and inflammatory events during hyperglycemia is critical for better 
clinical management.  
 
Diabetes Mellitus 
Diabetes mellitus is a medical condition that has become an epidemic and a 
public health concern in recent years.  The International Diabetes Federation 
estimates the current prevalence rate of 9.3% will be doubled by 20353. The 
American Diabetes Association confirms that 1.4 million Americans are diagnosed 
every year and 86 million Americans have prediabetes3.  The CDC reports Diabetes 
is the 7th leading cause of death, recording over 75,000 deaths in 20144. The expert 
committee on the diagnosis and classifications for diabetes mellitus criteria of 
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diagnosis is having hyperglycemia (high blood glucose) of or above 126 mg/dL 
while fasting for 8 hours due to insulin deficiency (type I) or resistance (type II) on 
more than one occurrence5.  Resistance to insulin is usually due to obesity or 
association with a metabolic syndrome.  The normal range for blood glucose levels 
are between 70 and 100 mg/dL.  Key complications of Diabetes are micro- and 
macro-vascular complications, such as hypertension, cardiovascular disease, 
blindness, kidney disease, and lower-limb amputation1.  In 2003-2006, 
cardiovascular disease death rates were 1.7 times higher among patients with 
diabetes than without4.  In 2010, the CDC also had confirmed that hospitalization 
rates for heart attacks and strokes were 1.8 and 1.5 times more likely in patients 
with diabetes respectively4.  The CDC also reported that from 2005-2008, 4.2 million 
(28.5%) adult diabetes patients had diabetic retinopathy and 4.4% had advanced 
retinopathy, which could lead to severe vision loss4.  Moreover, diabetes is 
responsible for 44% of all kidney failure cases in 20114.  Finally, 60% of non-
traumatic lower limb amputations occurred in patients diagnosed with diabetes4.   
 
Acute Hyperglycemia 
Acute hyperglycemia, otherwise known as stress hyperglycemia is defined as 
a condition in which blood glucose levels are above 126 mg/dL temporarily, without 
a known history of diabetes5.  It is typically due to surgery, critical illness, sepsis, 
and/or trauma.  It has been reported that stress hyperglycemia occurs 5-30% 
critical illness cases6.  Although acute hyperglycemia does not have all the 
deleterious impacts on a patient as diabetes, it still has been linked to numerous 
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complications such as a decrease in wound healing and immune function, an 
increase in myocardial infarctions (MI), post-surgical complications, extended 
hospital stays, as well as increased mortality rates. Yang et al (2009) determined 
that acute hyperglycemia increased infarct size (% region at risk) in mice from 34% 
to 49% (a 45% increase in infarct size)13.  In 2009, Cruz-Gonzalez et al. found a 
correlation between non-diabetic patients admitted with hyperglycemia and 
increase in infarct size.  They discovered that hyperglycemia was an independent 
predictor of infarct size and that hyperglycemia was associated with a larger infarct 
size23.  A randomized study by Richards et al (2014) demonstrate that surgical site 
infections (SSI) in orthopedic injuries were more common in patients with 
hyperglycemia (21.2%) than without (3.3%)16.  On a cellular level hyperglycemia 
has been linked to vascular endothelial dysfunction and subsequent inflammatory 
responses 10.     
 
Vascular Endothelial Cells and Vascular Endothelial Function 
Endothelial cells are a single layer of mesenchymal cells that line body 
cavities and vascular walls.  Endothelial cells specific to the lining of arteries, veins, 
and capillaries of the skin, heart, lungs, and brain are continuous and 
nonfenestrated, meaning there is no breaks in the endothelial lining and they lack 
pores for rapid exchange of molecules10.  They contain caveolae as well as transient 
receptor potential channels that assist in regulating fluid and macromolecule 
passage as well as vascular regeneration, increased permeability and endothelium-
derived NO mediated vasorelaxation10.  These cells produce factors such as 
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vasodilators (NO, prostaglandins,etc), vasoconstrictors (angiotensin II and 
endothelin-1), pro and anticoagulants (plasminogen activators and inhibitors, 
thrombomodulin, von Wilebrand factor,etc), and fibrinolytics and anti-fibrinolytics, 
growth factors (VEGF), to maintain normal vascular homeostasis or in response to 
vascular damages, respectively10.  Their luminal surfaces are capable of regulating 
trafficking of blood cells through their binding proteins and other molecules.  
Endothelial cells are also involved in innate and adaptive immunity as well as 
hemostasis by releasing inflammatory and anti-inflammatory factors (NO), adhesion 
factors (E-selectin, PECAM-1, VCAM-1, ICAM-1), as well as oxidizing and 
antioxidizing factors10.  Vascular endothelial cells play a key role in maintaining 
vascular homeostasis, vessel regulation, blood clotting and inflammation, as 
summarized by Favero et al. in figure 1.  In particular, endothelial nitric oxide 
synthase (eNOS) is a key component in vascular endothelial cells.   
 
Figure 1: Functions of Endothelial Cells in Physiological Conditions. 
Received from Favero, G. et al. Endothelium and Its Alterations in Cardiovascular 
Diseases: Life Style Intervention.  BioMed Research International. 1-28. (2014) 
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Endothelial nitric oxide synthase (eNOS)  
Endothelial nitric oxide synthase (eNOS), is diffusely distributed in the 
cytoplasm of endothelial cells10.  Endothelial cells express higher levels of eNOS 
after stress.  The enzyme releases NO which not only prevents inflammation, 
coagulant signals, and facilitates blood flow, but it is a key factor for maintaining 
vascular tone and reactivity.  NO is also responsible for inhibiting platelet and white 
blood cell activation and prevents actions of contracting factors such as angiotensin 
II and endothelin-1 (ET-1)10.  The eNOS enzyme has two domains with two separate 
functions, C-terminal reductase domain and an N-terminal oxygenase domain14.  
The C-terminal reductase domain produces electrons by way of FAD/NADPH and 
the FMN binding sequences it contains.  The N-terminal oxygenase domain binds 
BH4 and L-arginine and converts L-arginine to L-citrulline, and in the process, 
produces NO.  Both BH4 and L-arginine are essential for the generation of NO, as 
demonstrated by early studies showing that depletion of these factors results in SO 
formation instead of NO, which is described as eNOS uncoupling14. 
 
eNOS Uncoupling and SO Induced by Oxidative Stress 
In pathological conditions, oxidative stress can induce eNOS uncoupling, 
which shifts its product from NO to SO.  This shift from NO to SO also occurs in the 
N-terminal oxygenase domain, specifically at it’s heme center.  Recent studies also 
have also shown evidence that the C-terminal reductase domain produces SO in its 
FAD/NADPH and FMN binding sites14.  It has been understood for some time now 
that in the presence of SO, it can quickly quench nitric oxide (NO) to form 
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peroxynitrite, another more toxic free radical.  Peroxynitrite is responsible for 
uncoupling eNOS by oxidizing the complex as well as its cofactor BH4, demonstrated 
in figure 218. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Functions of eNOS, coupled and uncoupled.  
Retrieved from Schmidt, T. et al. Mechanisms for the role of tetrahydrobiopterin in 
endothelial function and vascular disease. Clin Sci (Lond). 113(2):47-63 
 
Youn, et al has also recently demonstrated recently, that Bone Morphogenic 
Protein 4 (BMP4), which is known for its activity during inflammation, endothelial 
dysfunction, and atherogenesis, has been linked to eNOS uncoupling17.  This was 
demonstrated by increased SO production as well as a decrease in BH4.   They also 
determined in this same study that NOX1 mediates BMP4-induced eNOS uncoupling, 
as shown by a diminished BMP4-induced eNOS uncoupling with NOX1 siRNA-
transfected cells17.  The product shift of uncoupled eNOS from NO to SO not only 
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diminishes NO bioavailability, but also increases SO products, resulting in greater 
oxidative stress. 
 
Vascular Endothelial Dysfunction Under Hyperglycemic Conditions 
Many studies have suggested that chronic and acute hyperglycemia can cause 
vascular endothelial dysfunction.  A meta-analysis conducted in 2015 documented 
that the effects of hyperglycemia are responsible for decreased macro- vascular 
function. Studies have demonstrated that macro-vascular function such as 
endothelium-dependent vasodilation through NO was also decreased due to acute 
hyperglycemia and suggests that acute hyperglycemia could be responsible for the 
vascular smooth muscle cell proliferation that is responsible for vascular 
remodeling, resulting in cardiovascular disease24.   
The deleterious effects of hyperglycemia have been presumed to be initiated 
by vascular endothelial dysfunction.  In type 1 diabetes, endothelial dysfunction is 
chiefly due to metabolic changes predominantly at the retinal and kidney level, 
however, in type 2 diabetes, endothelial dysfunction begins before onset13.  
Oxidative stress is believed to be a source of vascular endothelial dysfunction and 
increased inflammatory factors.  Oxidative stress is due to overproduced reactive 
oxygen species (ROS) overwhelming anti-oxidant mechanisms in the body.  ROS that 
mainly consist of overproduced superoxide (SO) and hydrogen peroxide (H2O2).  SO 
can be readily converted to H2O2 by superoxide dismutase (SOD).  H2O2 is much 
more stable than SO and remains for longer periods in the blood.  There are multiple 
sources of ROS, as previously mentioned, uncoupled eNOS, as well as mitochondria 
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under dysfunction, xanthine oxidase, and NADPH oxidase26.  All of these upregulate 
their production of SO under pathological conditions and in upregulation of NADPH 
oxidase26.   
As previously mentioned, overproduced SO can quickly quench nitric oxide 
(NO) to form peroxynitrite resulting in reduced endothelial-derived NO 
bioavailability.  Vascular endothelial dysfunction is not only identified by increased 
levels of ROS, but also by decreased levels of nitric oxide (NO).  Oxidative stress has 
been linked continuously to the progression of all types of diabetes as well as other 
pathological conditions.  Many sources have concluded that hyperglycemia is the 
cause of increased ROS, which then leads to other complications20,21. 
 
NADPH Oxidases 
NADPH oxidases are the only enzymes in the body that naturally produce 
SO/ H2O2. NADPH oxidases and also may be a principle source of SO/ H2O2 under 
hyperglycemic conditions that result in eNOS uncoupling.  There are a total of 7 
isoforms in mammals, NOX -1, -2, -3, -4, -5, and dual oxidase -1/-2.  NOX1 through 3 
share similar structures consisting of five subunits.  Each of these contains two 
transmembrane units, the NOX unit which is the catalytic unit, and the p22phox 
unit.  They also contain three cytosolic subunits, RAC1 which is a small GTPase 
responsible for regulation, p47phox/NOXO1 which is responsible for organization, 
and NoxA1/p67phox which is responsible for activation.   Angiotensin II (Ang II) is 
responsible for the upregulation of vascular NADPH oxidases in physiological 
conditions through activation of protein kinase C (PKC).  Once PKC is activated, it is 
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translocated to the membrane where it can phosphorylate the p47phox subunit of 
NADPH oxidase.  This phosphorylation causes assembly of the rest of the subunits 
while also triggers activation of a proto-oncogene, c-Src, to stimulate epidermal 
growth factor receptor (EGRF), creating a cascade of activations to activate the Rac1 
subunit and in turn activate NADPH oxidase22.   
 
 
Figure 3: NADPH Oxidase 1 Structure and Composition.  
Retrieved from Drummond, G, et al. Combating Oxidative stress in vascular disease: 
NADPH oxidases as therapeutic targets. 453-471. (2011) 
 
NADPH oxidases are responsible for electron transfer into the electron 
transport chain with oxygen as the final acceptor.  This electron transfer results in 
the NADPH oxidase releasing superoxide.  Some isoforms, such as Nox4, Duox1 and 
Duox 2 release hydrogen peroxide instead.  As previously stated, superoxide(SO) is 
not as stable as hydrogen peroxide(H2O2) and is quickly converted.  These enzymes 
are located in the constitutive cell’s arterial walls and are responsible for generation 
of ROS which leads to oxidative stress.  In physiological conditions, NADPH oxidases 
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(NOX) assist the body with innate immunity, redox-dependent signaling, and 
production of hormones. 
In pathological conditions, NADPH oxidases are responsible for the over 
production of ROS and oxidative stress in the body.  In pathological conditions, an 
up regulation of NADPH oxidase activation and activity thus leads to an increased 
and detrimental amount of ROS which causes irreversible damage to the 
vasculature.  NADPH oxidases are activated under hyperglycemic conditions 
through PKC. During hyperglycemia, the increased levels of glucose are responsible 
for providing increased levels of diacylglycerol (DAG) through glycolysis.  DAG is 
responsible for activating PKC, and has been accepted as the DAG-PKC pathway.  
This pathway has been known to regulate endothelial permeability as well as 
vascular function5.  Upregulation of PKC in turn upregulates activation of NADPH 
oxidases.   
PKC enzymes, specifically PKC Beta II become activated by hyperglycemia 
and translocate to the membrane.  This translocation as previously stated, puts 
them in proximity with the NADPH oxidases, causing phosphorylation of the NOX 
p47phox subunit.  Phosphorylation of this subunit stimulates the rest of the NOX 
subunits to assemble, thus activating the NADPH oxidase.  
It has also been recently discovered that NADPH oxidases may also have a 
role in activation of mitochondrial dysfunction through AngII22.  Dikalov found that 
inhibition of NADPH oxidases as well as PKC, prevented of mitochondrial 
dysfunction22.  Their studies show that mitochondrial function is associated with 
NADPH oxidase specific SO.  When there is an upregulation of SO and H2O2 by 
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NADPH oxidase, there is an opening of the mitoKATP channels, which leads to the 
dysfunction22.  This was demonstrated by using the NADPH oxidase inhibitors, 
apocynin and chelerythrine, which prevented mitochondrial dysfunction.  
Mitochondrial dysfunction leads to decreased membrane potential, respiratory 
control ratio, and the content of low molecular weight thiols.  The results of 
mitochondrial dysfunction include increased SO and H2O2 production on the 
mitochondrial complex I.  When the mitochondria had an increase in SO, there was 
an increase in cytoplasmic SO as well, suggesting that the mitochondria in turn 
upregulated NADPH oxidase activity22.  This further exacerbates the oxidative stress 
caused by NADPH oxidases, and creates a “cross-talk” of sorts between 
mitochondria and NADPH oxidases that results in a feed forward mechanism for 
oxidative stress22.   The study suggests that this cross talk activity could be mediated 
by c-Src..  Of the NADPH oxidases, only 1,2 and 4 are expressed in the vasculature, 
and only 1 and 2 in endothelial cells.   
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Figure 4. The possible vicious cycle involved in hyperglycemia-induced 
vascular endothelial dysfunction and oxidative stress.   
 
 
NADPH Oxidase 1 (NOX1) and NADPH Oxidase 2 (NOX2) 
Most NADPH oxidase isoforms are expressed in each cell type of the vascular 
wall.  Of these isoforms, NOX1 and NOX2 are mainly expressed in the vascular 
endothelial cells and vascular smooth muscle cells (VSMCs). Previous animal studies 
have determined NOX1 to be the main isoform associated with cardiovascular 
disease pathology3.   Previous studies also showed that NOX1 mRNA levels were 
elevated in the kidney during hyperglycemic conditions as well as deletion of NOX1 
attenuating hyperglycemic induced glomerular hypertrophy, mesangial matrix 
expansion, oxidative stress and cortical senescence, all of which are associated with 
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renal disease8.  NOX1 activity has also been linked as the major component of ROS 
and inflammatory cytokine induced beta cell dysfunction11.  
NOX2, on the other hand, did not show any attenuation of such factors 
causing diabetic kidney when tested with NOX2 Knock out mice9.  Previously, our 
lab has found NOX2 inhibitor, gp91ds-tat, only partially reduced blood H2O2 levels 
under hyperglycemic conditions.  However, the role of NOX1 in hyperglycemia 
induced oxidative stress and vascular endothelial dysfunction is still unclear.   
 
NOX1 Inhibitor: ML171 
High-throughput screening has identified a few phenothiazines that exhibit 
NOX1 inhibition.  It was discovered that 2-acetylphenothiazine, otherwise known as 
ML171, is currently the inhibitor most specific for NOX1, while having only marginal 
activity with other NADPH oxidases12.  ML171 was shown to have a 30-fold 
selectivity over other NOX isotypes.  This inhibitor works specifically and directly on 
the Nox1 subunit, previously mentioned as the catalytic unit of the enzyme.  It has 
been previously discovered that ML171 blocked ROS-dependent formation of 
extracellular matrix-degrading invadopodia in colon cancers and was reversed 
when over expression f NOX1 was introduced.  ML171 was the selective NOX1 
inhibitor as it is the best available at that time.   
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Hypothesis 
It was hypothesized that acute hyperglycemia (200 mg/dL) would increase 
blood H2O2 levels and decrease blood NO levels compared to saline control. By 
inhibiting NADPH Oxidase 1 phosphorylation/assembly/activation through 
ML171(2-acetylphenothiazine, MW=241.31 g/mol, Tocris Bioscience), acute 
hyperglycemia-induced vascular dysfunction would be attenuated.  This will be 
confirmed by decreased blood H2O2 levels and increased blood NO levels compared 
to acute hyperglycemia control.  
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Methods 
NO and H2O2 Calibrations 
Microsensors (100m, World Precision Instruments (WPI), Sarasota, FL) for 
NO and H2O2 were calibrated prior to the experiments using known concentrations 
of NO and H2O2 as per manufacturer’s suggestion.  The electrochemical 
microsensors membrane detects the NO and H2O2 and is analyzed in real-time using 
the Apollo 4000 Free Radical Anaylzer that allows measurement of multiple species 
at once and selective poise voltage for ranges needed.  Standard curves were used to 
convert electrochemical changes to concentrations.  Standard curves for NO were 
achieved by soaking the microsensor in 10 mL copper sulfate.  The baseline was 
recorded after at least 10 minutes of soaking, followed by added known amounts (0-
200 nM) of standard SNAP solution (100M- 00022 g S-Nitroso-N-Acetyl-D,L-
Penicillamine (SNAP) and 0.002 g ethylenediaminetetraaceitic acid (EDTA) were 
dissolved in 100 mL distilled water) were added and the differences were recorded.  
To obtain a standard curve for H2O2, the microsensor was soaked in 10 mL PBS 
buffer until stabilized.  Following the baseline measurement, known amounts (0-2 
M) of standard (1mM) H2O2 was added to develop a calibration formula.  The 
formulas determined from both standard curves were used to convert 
measurements obtained in real-time to concentrations of blood NO (nM) and blood  
H2O2 (M).  
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Animal Preparations 
All the procedures used in the animal experiments were approved by PCOM 
IACUC.  Male Sprague-Dawley rats (Charles River: Charles River Kinston, NC), 
ranging from 275-325g, were used in this study.  The rats were anesthetized with 
pentobarbital sodium 60mg/kg of 50mg/mL injections (i. p.).   Maintenance doses 
were titrated to effect at 30mg/kg (i.p.).  Surgical preparations to prepare animal for 
infusions and monitoring throughout the 180 minutes of the experiment are 
illustrated in figures 4 and 5.   
 
Figure 5. Isolation and catheterization of Jugular vein and Carotid artery.    
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Figure 6. Catheterization of both Femoral veins with inserted microsensors.    
 
The carotid artery was first catheterized in order to monitor status during 
the experiment (see figure 4-blue arrow). Proper operative conditions were 
monitored by recording mean arterial blood pressure (MABP) every 20 minutes, 
throughout the experimental period.  Normal MABP levels ranged from 90-
130mmHg during the entire experiment.  The jugular vein was catheterized to 
infuse saline, 30% D-glucose, or 30% D-glucose with ML171 (see figure 4-black 
arrow). Dose dependency was evaluated using 1M and 5M doses of ML171.  
Following, 1 mL Heparin was then administered to preclude blood clotting during 
intravenous infusion, as well as MABP monitoring via the carotid artery, and blood 
adherence to the membranes of the free radical sensors inserted into the femoral 
vein catheters.  Hyperglycemic conditions were induced with a loading dose of 30% 
D-glucose at 0.33mL/min for 3 minutes. Blood glucose levels were maintained 
around 200mg/dL for 3 hours by measuring blood glucose levels every 20 minutes 
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using a blood glucose meter and adjusting infusion rate accordingly (0.018-
0.025mL/min).  To determine NO and H2O2 levels in real time throughout the 
experiment, NO and H2O2 microsensors were inserted into catheters in both femoral 
veins and measured using the free radical analyzer (see figure 5).  Levels of NO and 
H2O2 were be measured as pA every 20 minutes until the end of the experiment and 
converted into concentration (nM for NO and μM for H2O2, respectively) using the 
calibration curves.  
 
Experimental Groups 
There were 4 experimental groups: 
1. Saline Controls (n=8 for NO and n=9 for H2O2) The animals had the same 
surgical conditions as experimental groups and were monitored for NO and 
H2O2 in a similar manner for 3-hour experimental period following the 1-
hour baseline readings.  This group was used to demonstrate stability of the 
physiological parameters under surgery, to demonstrate real-time NO and 
H2O2 levels, and served as a control for the to hyperglycemic group.  
2. Hyperglycemic groups (n=8 for NO and n=9 for H2O2) These animals were 
initially infused with 30% glucose to induce hyperglycemia then infused 
continuously with 30% glucose to maintain hyperglycemic conditions of 
≥200 mg/dL throughout the experiment.  The groups were used to 
demonstrate real-time NO and H2O2 under hyperglycemic conditions.  
3. Hyperglycemic groups + 1 μM ML171 (n=5 for NO and n=8 for H2O2) These 
animals were initially infused with 30% glucose to induce hyperglycemia 
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then infused continuously with 30% glucose to maintain hyperglycemic 
conditions of ≥200 mg/dL throughout the experiment.  These groups were 
used to demonstrate real-time NO and H2O2 under hyperglycemic conditions 
with the addition of the NOX1 inhibitor. 
4. Hyperglycemic groups + 5 1 μM ML171 (n=5 for NO and n=5 for H2O2) These 
animals were initially infused with 30% glucose to induce hyperglycemia 
then infused continuously with 30% glucose to maintain hyperglycemic 
conditions of ≥200 mg/dL throughout the experiment.  These groups were 
used to demonstrate real-time NO and H2O2 under hyperglycemic conditions 
with the addition of a higher dose of the NOX1 inhibitor. 
 
Outline of Experiment 
1. Calibrations 
2. Animal preparations-  
a. femoral veins: NO and H2O2 sensors  
b. Jugular vein: IV infusion with one of experimental group variations 
c. Carotid artery: measure MABP 
3. Run experiment-180 minutes 
a. Record: blood glucose, NO and H2O2 levels, MABP 
 
Statistical Analysis 
All data from text and figures were analyzed by ANOVA using post hoc 
analysis with the Student- Newman- Keuls post hoc test for pairwise comparison of 
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groups, p<0.05 were considered to be statistically significant.  They are represented 
as mean ± the standard error of the mean (SEM).  
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Results 
 
Acute Hyperglycemia levels maintained among groups 
Blood glucose levels among saline control, 30% D-glucose, 30% D-glucose 
with 1 M ML171, and 30% D-glucose with 5 M ML171 were illustrated in figure 6.  
The saline control remained in normal blood glucose range (<126mg/dL) for the 
entire experiment.  All three groups treated with 30% D-glucose maintained a blood 
glucose level over 200 mg/dL for the 180-minute experiment once fully induced.  
The treatment drug, ML171, showed no altering effects on blood glucose levels, for 
both the 1 M ML171, and 5 M ML171. 
 
Figure 7. Blood glucose changes throughout 180-minute experiment with 30% 
D-glucose.  Groups infused with 30% D-glucose maintained blood glucose 
levels of ≥200 mg/dL compared to saline (<126mg/dL). 
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Mean Arterial Blood Pressures Remained Normal throughout Experiment 
Mean arterial blood pressure (MABP) among saline control, 30% D-glucose, 
30% D-glucose with 1 M ML171, and 30% D-glucose with 5 M ML171 were 
shown in figure 7.  MABP remained in normal range (90-130mmHg) throughout the 
experiment.  Acute hyperglycemia as well as hyperglycemia combined with ML171 
had no effect on MABP, which were similar to that of the saline group.   
 
Figure 8. Mean Arterial Blood Pressure among groups taken every 20 minutes 
for 180-minute experiment. MABP among all groups remained remained in 
normal range 90-130mmHg for 3 hours.  
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Acute Hyperglycemia Decreased Blood NO compared to Saline Control 
Blood NO levels among saline control and 30% D-glucose were demonstrated 
in figure 8.  The 30% D-glucose group had significant decrease in blood NO levels 
after 60-minute infusion compared to the saline control.  This marked decrease was 
by a mean value of 37.00±5.12 nM relative to saline (P<0.05, n=8).  The significant 
reduction in blood NO levels continued and was 101.41±10.91 nM relative to the 
saline group at the end of the 180-minute infusion (P<0.01, n=8). 
 
 
 
 
Figure 9. The comparison of blood NO levels relative to saline with 30% D-
glucose (*p<0.05, **p<0.01 vs saline).  Hyperglycemic group had significantly 
reduced blood NO levels relative to saline. 
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Ml171 attenuated decreased blood NO due to acute hyperglycemia in a dose-
dependent matter 
Blood NO levels among 30% D-glucose, 30% D-glucose with 1 M ML171, 
and 30% D-glucose with 5 M ML171 relative to saline are shown in figure 9.  The 
30% D-glucose group, as previously stated, had a significant decrease in NO from 60 
minutes and throughout the rest of the experiment.  The blood NO levels were 
finally decreased by 101.41±10.91 nM relative to saline (P<0.01, n=8) .  By contrast, 
the 1 M ML171 attenuated the decrease in blood NO levels with significant 
improvement at 100 minutes until the end of experiment.  The blood NO levels were 
only reduced by 32.93±12.67 nM relative to saline at 180 minutes (P<0.01, n=5).  The 5 
M ML171 attenuated the decreased blood NO levels even further with significance 
seen at 80 minutes into the experiment and continued until completion at 180 
minutes with only a slight decrease of 15.46±8.13 nM relative to the saline group 
(P<0.01, n=5).  
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Figure 10. The comparison of blood NO levels relative to saline among 30% D-
glucose, 30% D-glucose with 1μM ML171, and 30% D-glucose with 5μM 
ML171(*p<0.05, **p<0.01 vs Glucose).  ML171 increases blood NO levels under 
hyperglycemia for both 1μM and 5μM ML171 compared to hyperglycemic 
group. 
 
 
Acute Hyperglycemia Increased Blood H2O2 compared to Saline Control 
 
Blood H2O2 levels among saline control and 30% D-glucose are shown figure 
10.  The 30% D-glucose group had significant increase in blood H2O2 levels after 80 
minutes with an elevation of 1.37±0.21 M compared to saline group (P<0.05, n=9).  
The increase in blood H2O2 resulted in a final increase at 180- minutes of 3.06±0.42 
M compared to saline (P<0.01, n=9).  
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Figure 11. The comparison of blood H2O2 levels relative to saline with 30% D-
glucose (*p<0.05, **p<0.01 vs saline).  Hyperglycemic group had significantly 
elevated blood H2O2 levels relative to saline. 
 
 
Ml171 attenuated increased blood H2O2 due to Acute Hyperglycemia in dose 
dependent matter 
Blood H2O2 levels among 30% D-glucose, 30% D-glucose with 1 M ML171, 
and 30% D-glucose with 5 M ML171 were demonstrated in figure 11.  The 30% D-
glucose group, as previously stated, had a significant increase in H2O2 starting at 80 
minute infusion and continuing until 180 minutes, with a final elevation of 3.06±0.42 
M relative to saline (P<0.01, n=9).  The 1 M ML171 attenuated the increase in blood 
H2O2 levels with significance at 80 minutes as well as at 140 and 180 minutes 
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concluding with lower H2O2 levels of 1.20±0.61 M relative to saline (P<0.05, n=8).  
The 5 M ML171 attenuated the increased blood H2O2 levels even further with 
significance seen starting at just 40 minutes into the experiment and continued until 
completion at 180 minutes with blood H2O2 levels resulting 1.79±1.02 M (P<0.01, 
n=5) lower than the saline control.  
 
Figure 12. The comparison of blood H2O2 levels relative to saline among 30% 
D-glucose, 30% D-glucose with 1μM ML171, and 30% D-glucose with 5μM 
ML171(*p<0.05, **p<0.01 vs Glucose).  ML171 reduced blood H2O2 levels 
under hyperglycemia for both 1μM and 5μM ML171 compared to 
hyperglycemic group. 
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Discussion 
These results indicated that during hyperglycemia the blood NO levels were 
significantly reduced over the 3-hour experiment when compared to saline control.  
The results also demonstrated that blood H2O2 levels were significantly elevated 
over the 3-hour experiment when compared to saline control.   
With the addition of ML171, a selective inhibitor of NOX1, the reduced levels 
of NO seen in hyperglycemic conditions were attenuated during the 3-hour 
experiment.  ML171 also attenuated the elevation in blood H2O2 due to 
hyperglycemia.  The higher dose of ML171 (e.g. 5M) provided more beneficial 
effects in restoring blood NO levels and reducing blood H2O2 levels compared to the 
lower dose of ML171 (e.g. 1 M).   
Acute hyperglycemia has been shown to reduce vascular endothelial 
dependent vasodilation.  In 1998, Akbaris et al had determined that endothelium-
dependent vasodilation is impaired during acute hyperglycemia in both the micro- 
and macrocirculation in 20 healthy subjects27.  The macrocirculation diameter was 
monitored through the brachial artery by using high-resolution ultra sound before 
(fasting) and after ingesting 75 g of glucose.  The microcirculation diameter was 
measured by changes in the erythrocyte flux after acetylcholine iontophoresis.  
Their results showed that dilation was greater during fasting compared to 
hyperglycemia, suggesting that this impairs dilation.  Moreover, animal experiments 
also suggest that acute hyperglycemia can induce vascular endothelial dysfunction.  
Gross et al, in 2010 came to such conclusions analyzing shear stress to the left 
anterior descending coronary arteries(LAD) in dogs.  The animals were fasted, 
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anesthetized, and infused with different doses of glucose, depending on their group.  
The blood flow, diameter and velocity were measured with response to 
acetylcholine to measure endothelial function and ROS generation was determined 
by fluorescence of myocardial biopsies.  This study determined that hyperglycemia 
affects endothelial dysfunction in a dose related manner, as well as ROS production, 
and decreased shear stress28.  The induction of vascular endothelial dysfunction 
may also depend on the time length of acute hyperglycemia and blood vessel.  This 
was seen with McNauty et al in 2011 while measuring the coronary blood flow 
velocity and diameter in 12 cardiac transplant patients before and after 60-minute 
glucose infusion.  They found that although there were higher levels of oxidative 
stress, there was no difference in dilated segments or increase blood flow29.  They 
suggested that the endothelial dysfunction operates over a longer period of time29.   
This study directly monitors blood NO levels which may serve as a biomarker 
for vascular endothelial dysfunction in real time under acute hyperglycemia.  The 
current experimental study induced acute hyperglycemia with blood glucose levels 
of approximately 200- 300 mg/dL for 3 hours. Results determined that blood NO 
levels were significantly reduced in the hyperglycemia group compared to saline 
(101.41±10.91 nM; n=8).   When considering absolute values from previous studies 
such as Giustarini et al. in 2004, which found that by measuring nitrites in the 
plasma of 20 healthy patients it depicted relative levels of NO in the blood34.  This is 
assumed because nitrites are found to be the most concentrated form of storage NO 
carrier34.  They determined that the average amounts of nitrite in healthy 
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individuals were measured to be 221±72 nM34.  Relating back to the current study, 
NO bioavailability reduction due to hyperglycemia could be very significant.  
Many studies indicate that acute hyperglycemia can quickly induce blood 
oxidative stress and certain molecules can reverse some effects to an extent.  Gross 
et al had also found that the effects of superoxide dismutase mimetic 4-hydroxy-
2,2,6,6,-tetramethylpiperidine-1-oxyl, otherwise known as tempol, normalized the 
oscillatory shear stress that was decreased due to hyperglycemia28.  Title et al, in 
2007 found that Vitamins C and E attenuated the decrease in flow-mediated dilation 
caused by hyperglycemia30.  Oxidative stress in some studies is analyzed by lipid 
peroxidation(LPO).  LPO occurs when the free radical attack polyunsaturated FA 
and further interacts with heavy metals resulting in alkoxyl or peroxl radical that 
can continue a chain reaction21.  Iron salts can also react with the LPO, resulting in 
membrane structure changes21.  LPO may cause further damage to patients with 
hyperglycemia and diabetes through oxidation of enzymes, stimulation of 
proinflammatory cytokines, degenerative changes, and DNA damage25.  Lipid 
peroxidation(LPO) is typically measured using Malondialdehyde (MDA) because it is 
an end product of LPO and is a tag for oxidative stress.  Bastos et al, when studying 
the impact of systemic and local LPO level on periodontal inflammation and disease 
had found that uncontrolled diabetic patients had 2.5 times higher MDA plasma 
levels than non-diabetic, and 1.5 times higher for well controlled diabetic patients25.  
LPO was significantly higher in diabetes patients, with a strong correlation 
(p<0.0001).  They also discovered that there was positive association between local 
inflammatory cytokines in the gingival crevicular fluid with diabetic patients.  This 
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also supports previous findings about decreased wound healing due to diabetes and 
hyperglycemia25.  The current study measured oxidative stress through a real-time 
micro sensor for H2O2.  Real-time H2O2 was measured instead of the SO produced 
since SO is quickly converted to H2O2 by superoxide dismutase and is not as stable 
as H2O2.  The results determined that blood H2O2 levels were significantly elevated 
in the hyperglycemia group compared to saline.  Although the absolute values of 
H2O2 in the blood have been controversial, a recent study by Forman et al. has 
complied research and analyzed possible true values for H2O235.  They postulate that 
the normal range of H2O2 in the blood is between 1-5 µM35.   When considering this 
with the current study with hyperglycemia increasing blood H2O2 by 3.0 ± 0.5 µM, 
the amount of elevation could be significant and detrimental to physiological 
conditions.   
The application of antioxidants for counteracting the oxidative stress which 
participates in cardiovascular diseases is questionable due to failure of clinical trials.  
Vitamin E has been the main vitamin of focus for antioxidant capabilities, but 
despite promising cohort studies, randomized clinical intervention trials have failed 
to show any benefit for preventing atherosclerosis or cardiovascular events33.  
There also has been reason to question targeting ROS with antioxidants, because 
they may only be specific in reducing the concentration of some ROS, but not the 
others33.  Therefore, it may be more advantageous to determine the major and initial 
source for oxidative stress under hyperglycemia.   
NADPH oxidases are responsible for the natural production of SO/H2O2 in the 
body.  Under physiological conditions this is used to assist the body with innate 
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immunity, redox-dependent signaling, and production of hormones33.  In 
pathological conditions, activation of NADPH oxidases may serve as a key 
component in mediating hyperglycemia caused oxidative stress and vascular 
endothelial dysfunction.  Taye et al found that by inhibiting NADPH oxidase with 
apocynin, a specific NAPDH oxidase inhibitor, the elevated levels of their subunit, 
p47phox were lower as well as the oxidative stress due to hyperglycemia31.  Activated 
NADPH oxidase will produce a large amount of SO/H2O2.  Moreover, it can cross-talk 
and recruit other possible sources of oxidative stress, such as xanthine oxidase, 
eNOS uncoupling, and mitochondria, such upregulation of one will activate 
another22.  Ago, et al has suggested that xanthine oxidoreductase exists in 2 forms in 
order to assist in protein catabolism, xanthine dehydrogenase and xanthine 
oxidase26.  They state, that in oxidative stress, the oxidoreductase exists primarily in 
the xanthine oxidase form, producing SO26.  Current studies have also identified a 
possible “cross-talk” with mitochondria of NADPH oxidases in the vasculature22.  
The elevation of NADPH oxidase specific SO and H2O2 causes mitochondrial 
dysfunction, leading to the upregulation of SO produced by the mitochondria22.  This 
production of SO from the mitochondria in turn further activates the NADPH 
oxidases.  Furthermore, overproduction of ROS from mitochondria can further cause 
eNOS uncoupling.  The eNOS enzyme is then uncoupled, and instead of forming NO 
to protect homeostasis and regulation, eNOS quenches SO and peroxinitrite 
(another free radical) is formed.  Thus, the futile cycle resulting in endothelial 
dysfunction is created.  The damage associated with elevated ROS is in part due the 
eNOS uncoupling by the SO.  The free radical SO quenches NO and forms 
 33 
peroxinitite.  This is an even more toxic free radical, due to its ability to uncouple 
eNOS.  This is accomplished by oxidizing the complex as well as its cofactor BH4 18.  
NADPH oxidases are expressed throughout the body.  NOX1, 2 and 4 are 
expressed specifically in the vasculature, with 1 and 2 present in endothelial cells.  
NOX1 is also highly expressed in VSMCs26.  Bertolet et al has shown that NOX2 
inhibition with gp91ds-tat has only shown partial attenuation of H2O2 under 
hyperglycemia7.  The role of NOX1 in acute hyperglycemia is unclear.  Weaver et al, 
research had found that NOX1 inhibition can preserve the function of pancreatic 
beta cells through the use of ML17111.  We found that ML171 can attenuate the 
oxidative stressed caused by the upregulated NOX1 during hyperglycemia.   
  NOX1 inhibition can reduce PKC activation, which is the upstream signaling 
of NADPH oxidase activation.  In diabetic kidney, NOX1 has been suggested to be 
linked to activation of PKC activation8.  This is the first proposed feed forward 
mechanism of NOX1 with PKC.  It was also suggested that NOX1 but not NOX2 
mRNA expression was elevated in early hyperglycemia8.  NOX1 deficient mice had 
reduced oxidative stress and reduced activation of PKC.  NOX1 in hyperglycemia 
induced oxidative stress and vascular endothelial dysfunction was focus of our 
hypothesis.   
It was suggested by Youn, et al that NOX1 mediates BMP4-induced eNOS 
uncoupling, shown by a diminished BMP4-induced eNOS uncoupling with NOX1 
siRNA-transfected cells17.  This was demonstrated by eNOS uncoupling present 
within endothelial cells when exposed to BMP4 or bone morphological protein 417.  
NO is responsible for vasodilation, inhibiting platelet, and white blood cell 
 34 
activation.  These actions are necessary for maintaining vascular homeostasis.  The 
product shift of uncoupled eNOS from NO to SO not only diminishes NO 
bioavailability that maintains homeostasis, but also increases SO products, which 
results in more oxidative stress.  The possible mechanism of what may occur in the 
instance of blocking NOX1 with its involvement with other enzymes is outlined in 
figure 13.  The current study found that ML171, a selective NOX1 inhibitor, 
significantly reduced acute hyperglycemia-induced H2O2 increase and NO decrease. 
The higher dose provided better effects than lower dose. 
 
 
 
 
 
 
 
Figure 13. Possible mechanism of NOX1 activity at the endothelial level. NOX1 
may influence other enzymes and their production of SO.  
 
 To further understand the role of NOX1 in hyperglycemia-induced vascular 
dysfunction and oxidative stress, future studies will be designed to measure blood 
nitrite and other oxidative stress indicators such as Malondialdehyde (MDA).  The 
impact of body temperature on blood NO and H2O2 levels also were measured, NO 
levels slightly decreased in the saline control group and there was a slight increase 
in H2O2.  Future studies could employ westernblot and immunohistochemistry to 
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understand the mechanism as well as interaction of NOX1 with mitochondrial ROS, 
uncoupled eNOS, and PKC under the present experimental conditions.   
Future studies include clarifying the effects of body temperature, to rule out 
any variables due to heat loss during experiment.  A heating pad will be placed 
under the animals for the duration of the study. The long term effects of ML171 has 
also not yet been explored, and this could be an additional aspect of future studies.   
The results of this study must be considered in light of certain limitations; for 
the absolute values could not be measured.  The lab has not yet confirmed the blood 
plasma for H2O2 and NO, but a method to do so will be incorporated into future 
studies.  The free radical microsensors used in this study are also sensitive to 
movement and other variables, which may influence real-time readings.  Future 
studies may incorporate other ways to measure NO and H2O2 in real-time by use of 
fluorescence kits if a protocol is developed successfully for this experimental design.   
 
Summary 
Acute hyperglycemia is harmful, and the futile cycle created by NOX1 and 
uncoupling of eNOS is responsible for vascular endothelial damage.  Focus on 
reduction of oxidative stress by inhibiting NOX1 may prevent the vicious cycle of 
causing oxidative stress and NO reduction in the blood due to hyperglycemia.   
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